Novanta Inc. (NASDAQ:NOVT – Get Free Report) CEO Matthijs Glastra sold 7,500 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $179.70, for a total transaction of $1,347,750.00. Following the completion of the transaction, the chief executive officer now directly owns 56,382 shares of the company’s stock, valued at approximately $10,131,845.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Novanta Stock Down 2.6 %
Shares of NASDAQ NOVT opened at $170.17 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.79 and a quick ratio of 1.81. The company has a market cap of $6.11 billion, a P/E ratio of 101.90 and a beta of 1.29. Novanta Inc. has a 1 year low of $126.65 and a 1 year high of $187.12. The firm has a 50-day simple moving average of $174.15 and a two-hundred day simple moving average of $170.49.
Novanta (NASDAQ:NOVT – Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The technology company reported $0.85 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.85. The business had revenue of $244.40 million during the quarter, compared to the consensus estimate of $242.33 million. Novanta had a net margin of 6.52% and a return on equity of 15.20%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.85 earnings per share. Research analysts anticipate that Novanta Inc. will post 3.03 earnings per share for the current year.
Institutional Trading of Novanta
Wall Street Analyst Weigh In
Separately, Robert W. Baird lowered their price target on shares of Novanta from $175.00 to $169.00 and set a “neutral” rating for the company in a report on Wednesday, November 6th.
Read Our Latest Stock Report on Novanta
Novanta Company Profile
Novanta Inc, together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation.
Read More
- Five stocks we like better than Novanta
- What Does Downgrade Mean in Investing?
- Shopify Stock Rally Continues: Why the Growth Story Isn’t Over
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Tariff Troubles: 3 Stocks Planning Higher Prices
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Mercer Near Rock Bottom: Is This High-Yield Play Set to Soar?
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.